1. Home
  2. ORMP vs STTK Comparison

ORMP vs STTK Comparison

Compare ORMP & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Oramed Pharmaceuticals Inc.

ORMP

Oramed Pharmaceuticals Inc.

HOLD

Current Price

$2.88

Market Cap

104.6M

Sector

Health Care

ML Signal

HOLD

Logo Shattuck Labs Inc.

STTK

Shattuck Labs Inc.

HOLD

Current Price

$2.08

Market Cap

119.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ORMP
STTK
Founded
2002
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
104.6M
119.0M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
ORMP
STTK
Price
$2.88
$2.08
Analyst Decision
Hold
Analyst Count
0
5
Target Price
N/A
$3.00
AVG Volume (30 Days)
260.9K
116.1K
Earning Date
11-13-2025
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
838.25
N/A
EPS
1.03
N/A
Revenue
$2,000,000.00
$1,000,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$2.78
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.82
$0.69
52 Week High
$3.09
$2.71

Technical Indicators

Market Signals
Indicator
ORMP
STTK
Relative Strength Index (RSI) 71.35 54.27
Support Level $2.38 $1.93
Resistance Level $2.99 $2.18
Average True Range (ATR) 0.16 0.17
MACD 0.06 0.02
Stochastic Oscillator 83.78 70.01

Price Performance

Historical Comparison
ORMP
STTK

About ORMP Oramed Pharmaceuticals Inc.

Oramed Pharmaceuticals Inc is a pharmaceutical company that is engaged in the research and development of pharmaceutical solutions with a technology platform that allows for the oral delivery of therapeutic proteins. developed an oral dosage form intended to withstand the harsh environment of the stomach and effectively deliver active biological insulin or other proteins. Its product pipeline includes ORMD-0801, ORMD-0801, and ORMD 0901.

About STTK Shattuck Labs Inc.

Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.

Share on Social Networks: